A2A antagonists as novel nondopaminergic therapy for motor dysfunction in PD

Neurology

Volumn 61, Issue 11 SUPPL. 6, 2003, Pages

  Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; HALOPERIDOL; ISTRADEFYLLINE; LEVODOPA; OXIDOPAMINE; RESERPINE; ADENOSINE A2A RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; PURINE DERIVATIVE;

ACETYLCHOLINE RELEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; LOCOMOTION; MONOTHERAPY; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TREATMENT OUTCOME; ANIMAL; CORPUS STRIATUM; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; BASAL GANGLIA; CORPUS STRIATUM; DOPAMINE AGONISTS; DRUG SYNERGISM; HUMANS; MOTOR ACTIVITY; PARKINSON DISEASE; PURINES; RECEPTOR, ADENOSINE A2A;

EID: 0345600914     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000095209.59347.79     Document Type: Article

References (75)

1. Jankovic JJ. Therapeutic strategies in Parkinson's disease. In: Jankovic JJ, Tolosa E, eds. Parkinson's Disease and Movement Disorders. Philadelphia: Lippincott Williams & Wilkins, 2002:116-151.
2. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23:S2-S7.
3. Quinn NP. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998;51:S25-S29.
4. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
5. Jenner P, Rupniak NM, Rose S, et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 1984;50:85-90.
6. Bedard PJ, Di Paolo T, Falardeau P, Boucher R. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 1986;379:294-299.
7. Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1987;78:273-280.
8. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 1995;10:731-740.
9. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989;34:193-196.
10. Blanchet PJ, Grondin R, Bedard PJ. Dyskinesia and wearing-off following D1 agonist treatment in drug-naive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disord 1996;11:91-94.
11. Kuoppamaki M, Al Barghouthy G, Jackson M, et al. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa. Mov Disord 2002;17:1312-1317.
12. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998;13:871-876.
13. Jenner P. Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol 2000;247(suppl 2):43-50.
14. Jenner P. The relevance of adenosine A2a antagonists to the treatment of Parkinson's disease: concluding remarks. In: Kase H, Richardson PJ, Jenner P, eds. Adenosine Receptors and Parkinson's Disease. San Diego: Academic Press, 2000:257-263.
15. Kase H. New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia. Biosci Biotechnol Biochem 2001;65:1447-1457. Review.
16. Ongini E, Fredholm BB. Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci 1996;17:364-372.
17. Richardson PJ, Kase H, Jenner PG. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997;18:338-344.
18. Svenningsson P, Moine C, Fisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A2a receptors. Prog Neurobiol 1999;59:355-396.
19. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23:S8-19.
20. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
21. Crossman AR. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987;21:1-40.
22. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
23. Penney JB Jr, Young AB. Striatal inhomogeneities and basal ganglia function. Mov Disord 1986;1:3-15.
24. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 2000;47:S22-S32.
25. Fredholm BB, Abbracchio MP, Burnstock G, et al. Nomenclature and classification of purinoceptors. Pharmacol Rev 1994;46:143-156.
26. Olah ME, Stiles GL. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu Rev Pharmacol Toxicol 1995;35:581-606.
27. Augood SJ, Emson PC. Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a coexpression study. Brain Res Mol Brain Res 1994;22:204-210.
28. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1996;118:1461-1468.
29. Fink JS, Weaver DR, Rivkees SA, et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res Mol Brain Res 1992;14:186-195.
30. Schiffmann SN, Libert F, Vassart G, Vanderhaeghen JJ. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci Lett 1991;130:177-181.
31. Svenningsson P, Le Moine C, Aubert I, Burbaud P, Fredholm BB, Bloch B. Cellular distribution of adenosine A2A receptor mRNA in the primate striatum. J Comp Neurol 1998;399:229-240.
32. Nonaka H, Ichimura M, Takeda M, et al. KF17837 ((E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist. Eur J Pharmacol 1994;267:335-341.
33. Nonaka H, Mori A, Ichimura M, et al. Binding of [3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes. Mol Pharmacol 1994;46:817-822.
34. Shimada J, Kioke N, Nonaka H, et al. Adenosine A2a antagonists with potent anti-cataleptic activity. Nio Med Chem Lett 1997;7:2349-2352.
35. Shimada J, Suzuki F, Nonaka H, Ishii A, Ichikawa S. (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines. Potent and selective adenosine A2 antagonists. J Med Chem 1992;35:2342-2345.
36. El Yacoubi M, Ledent C, Parmentier M, Ongini E, Costentin J, Vaugeois JM. In vivo labelling of the adenosine A2A receptor in mouse brain using the selective antagonist [3H]SCH 58261. Eur J Neurosci 2001;14:1567-1570.
37. Jarvis MF, Williams M. Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. Eur J Pharmacol 1989;168:243-246.
38. Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol 1998;401:163-186.
39. Svenningson P, Hall H, Sedvall G, Fredholm BB. Distribution of adenosine receptors in the post mortem human brain: an extended autoradiographic study. Synapse 1997;27:322-335.
40. Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991;57:1062-1067.
41. Kurokawa M, Kirk IP, Kirkpatrick KA, Kase H, Richardson PJ. Inhibition by KF17837 of adenosine A2A receptor-mediated modulation of striatal GABA and ACh release. Br J Pharmacol 1994;113:43-48.
42. Mori A, Shindou T, Ichimura M, Nonaka H, Kase H. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci 1996;16:605-611.
43. Shindou T, Mori A, Kase H, Ichimura M. Adenosine A2a receptor enhances GABA(A)-mediated IPSCs in the rat globus pallidus. J Physiol 2001;532:423-434.
44. Hettinger BD, Lee A, Linden J, Rosin DL. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol 2001;431:331-346.
45. Gubitz AK, Widdowson L, Kurokawa M, Kirkpatrick KA, Richardson PJ. Dual signalling by the adenosine A2a receptor involves activation of both N- and P-type calcium channels by different G proteins and protein kinases in the same striatal nerve terminals. J Neurochem 1996;67:374-381.
46. Kurokawa M, Koga K, Kase H, Nakamura J, Kuwana Y. Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo. J Neurochem 1996;66:1882-1888.
47. Richardson PJ, Kurokawa M. Regulation of neurotransmitter release in basal ganglia by adenosine receptor agonist and antagonists in vitro and in vivo. In: Richardson PJ, Kase H, Jenner PG, eds. Adenosine Receptors and Parkinson's Disease. San Diego: Academic Press, 2000:129-148.
48. Franco R, Ferre S, Agnati L, et al. Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology 2000;23:S50-S59.
49. Aoyama S, Kase H, Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 2000;20:5848-5852.
50. Chen J-F, Moratalla R, Impagnatiello F, et al. The role of the D2 dopamine receptor (D2R) in A2a adenosine receptor (A2aR)-mediated behavioral and cellular responses as revealed by A2a and D2 receptor knockout mice. Proc Natl Acad Sci USA 2001;98:1970-1975.
51. Dassesse D, Massie A, Ferrari R, et al. Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J Neurochem 2001;78:183-198.
52. Zahniser NR, Simosky JK, Mayfield RD, et al. Functional uncoupling of adenosine A(2A) receptors and reduced response to caffeine in mice lacking dopamine D2 receptors. J Neurosci 2000;20:5949-5957.
53. Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J Neurosci 2000;20:7782-7789.
54. Hauber W, Neuscheler P, Nagel J, Muller CE. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur J Neurosci 2001;14:1287-1293.
55. Shiozaki S, Ichikawa S, Nakamua J, Kuwana Y. Effects of Adenosine receptors. In: Kase H, Richardson PJ, Jenner P, eds. Adenosine Receptors and Parkinson's Disease. San Diego: Academic Press, 2000:193-210.
56. Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl) 1999;147:90-95.
57. Fenu S, Pinna A, Ongini E, Morelli M. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 1997;321:143-147.
58. Koga K, Kurokawa M, Ochi M, Nakamura J, Kuwana Y. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol 2000;408:249-255.
59. Pinna A, Corsi C, Carta AR, Valentini V, Pedata F, Morelli M. Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol 2002;446:75-82.
60. Kanda T, Jenner P. Actions of adenosine antagonists in primate model of Parkinson's disease. In: Kase H, Richardson PJ, Jenner P, eds. Adenosine Receptors and Parkinson's Disease. San Diego: Academic Press, 2000:211-227.
61. Lundblad M, Vaudano E, Cenci MA. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of 1-DOPA-induced dyskinesia. J Neurochem 2003;84:1398-1410.
62. Fredduzzi S, Moratalla R, Monopoli A, et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci 2002;22:1054-1062.
63. Ochi M, Koga K, Kurokawa M, Kase H, Nakamura J, Kuwana Y. Systemic administration of adenosine A2a receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 2000;100:53-62.
64. Kanda M, Jackson MM, Smith LA, et al. Adenosine A2a antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
65. Kanda T, Tashiro T, Kuwana Y, Jenner P. Modulation of motor function by adenosine A2a receptors in parkinsonian common marmosets. Neuroreport 1998;9:2857-2860.
66. Zeng BY, Pearce RK, MacKenzie GM, Jenner P. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 2000;12:1096-1104.
67. Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000;162:321-327.
68. Grondin R, Bedard PJ, Hadj TA, Gregoire L, Mori A, Kase H. Antiparkinsonian effect of a new selective adenosine A2a receptor antagonist in MPTP-treated monkeys. Neurology 1999;52:1673-1677.
69. Tahar AH, Grondin R, Gregoire L, Bedard PJ. Selective adenosine A2a receptor antagonism as an alternative therapy for Parkinson's disease. A study in nonhuman primates. In: Kase H, Richardson PJ, Jenner P, eds. Adenosine Receptors and Parkinson's Disease. San Diego: Academic Press, 2000:229-263.
70. Augood SJ, Emson PC, Standaert DG. Localisation of adenosine receptors in brain and periphery. In: Kase H, Richardson PJ, Jenner P, eds. Adenosine Receptors and Parkinson's Disease. San Diego: Academic Press, 2000:17-30.
71. Chen JF, Steyn S, Staal R, et al. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. J Biol Chem 2002;277:36040-36044.
72. Chen JF, Xu K, Petzer JP, et al., Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001;21:RC143.
73. Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002;80:262-270.
74. Morelli M, Wardas J. Adenosine A2a receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. Neurotox Res 2001;3:545-556.
75. Wardas J. Neuroprotective role of adenosine in the CNS. Pol J Pharmacol 2002;54:313-326.